Primary objective: To evaluate the safety and tolerability of JH013 after a single dose in healthy subjects; Secondary objective: To evaluate the pharmacokinetic and pharmacodynamic characteristics of JH013 after a single dose in healthy subjects and the immunogenicity of JH013

Start Date-

Sponsor / Collaborator

Ambotek Pharmaceutical Co., Ltd.

[+1]

NCT06633055 / Not yet recruitingPhase 1

A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JH013 Injection in Healthy Subjects

This is a phase I clinical trial with a single dose escalation to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JH013 injection in healthy subjects

Start Date31 Oct 2024

Sponsor / Collaborator

Biotech Pharmaceutical Co., Ltd.

100 Clinical Results associated with JH-013

100 Translational Medicine associated with JH-013

100 Patents (Medical) associated with JH-013

Literatures (Medical) associated with JH-013

01 Dec 2016·BMC BiotechnologyQ4 · ENGINEERING & TECHNOLOGY

Enhancement of D-lactic acid production from a mixed glucose and xylose substrate by the Escherichia coli strain JH15 devoid of the glucose effect

Q4 · ENGINEERING & TECHNOLOGY

ArticleOA

Author: Zhou, Shengde ; Manow, Ryan ; Lu, Hongying ; Zhao, Xiao ; Iverson, Andrew ; Wang, Yongze ; Ding, Xiaoren ; Wang, Jinhua ; Garza, Erin

BACKGROUNDA thermal tolerant stereo-complex poly-lactic acid (SC-PLA) can be made by mixing Poly-D-lactic acid (PDLA) and poly-L-lactic acid (PLLA) at a defined ratio. This environmentally friendly biodegradable polymer could replace traditional recalcitrant petroleum-based plastics. To achieve this goal, however, it is imperative to produce optically pure lactic acid isomers using a cost-effective substrate such as cellulosic biomass. The roadblock of this process is that: 1) xylose derived from cellulosic biomass is un-fermentable by most lactic acid bacteria; 2) the glucose effect results in delayed and incomplete xylose fermentation. An alternative strain devoid of the glucose effect is needed to co-utilize both glucose and xylose for improved D-lactic acid production using a cellulosic biomass substrate.RESULTSA previously engineered L-lactic acid Escherichia coli strain, WL204 (ΔfrdBC ΔldhA ΔackA ΔpflB ΔpdhR ::pflBp6-acEF-lpd ΔmgsA ΔadhE, ΔldhA::ldhL), was reengineered for production of D-lactic acid, by replacing the recombinant L-lactate dehydrogenase gene (ldhL) with a D-lactate dehydrogenase gene (ldhA). The glucose effect (catabolite repression) of the resulting strain, JH13, was eliminated by deletion of the ptsG gene which encodes for IIBC(glc) (a PTS enzyme for glucose transport). The derived strain, JH14, was metabolically evolved through serial transfers in screw-cap tubes containing glucose. The evolved strain, JH15, regained improved anaerobic cell growth using glucose. In fermentations using a mixture of glucose (50 g L(-1)) and xylose (50 g L(-1)), JH15 co-utilized both glucose and xylose, achieving an average sugar consumption rate of 1.04 g L(-1)h(-1), a D-lactic acid titer of 83 g L(-1), and a productivity of 0.86 g L(-1) h(-1). This result represents a 46 % improved sugar consumption rate, a 26 % increased D-lactic acid titer, and a 48 % enhanced productivity, compared to that achieved by JH13.CONCLUSIONSThese results demonstrated that JH15 has the potential for fermentative production of D-lactic acid using cellulosic biomass derived substrates, which contain a mixture of C6 and C5 sugars.

12 Sep 2016·Journal of Clinical InvestigationQ1 · MEDICINE

Interruption of progerin–lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype

Q1 · MEDICINE

Article

Author: So Mi Kang ; So Young Jun ; Ho Young Chun ; Tae Gyun Woo ; Min Ho Yoon ; Carlos López-Otín ; José M.P. Freije ; Nam Chul Ha ; Kyeong Lee ; Youn Sang Jung ; Clea Bárcena ; Su Jin Lee ; Guanghai Jin ; Gyu Yong Song ; Bum Joon Park ; Sang Kyum Kim ; Jee Hyun Lee ; Kyu Jin Chung ; Min Kyun Na ; Ah Young Oh ; Ho Young Lee

Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant genetic disease that is caused by a silent mutation of the LMNA gene encoding lamins A and C (lamin A/C). The G608G mutation generates a more accessible splicing donor site than does WT and produces an alternatively spliced product of LMNA called progerin, which is also expressed in normal aged cells. In this study, we determined that progerin binds directly to lamin A/C and induces profound nuclear aberrations. Given this observation, we performed a random screening of a chemical library and identified 3 compounds (JH1, JH4, and JH13) that efficiently block progerin-lamin A/C binding. These 3 chemicals, particularly JH4, alleviated nuclear deformation and reversed senescence markers characteristic of HGPS cells, including growth arrest and senescence-associated β-gal (SA-β-gal) activity. We then used microarray-based analysis to demonstrate that JH4 is able to rescue defects of cell-cycle progression in both HGPS and aged cells. Furthermore, administration of JH4 to LmnaG609G/G609G-mutant mice, which phenocopy human HGPS, resulted in a marked improvement of several progeria phenotypes and an extended lifespan. Together, these findings indicate that specific inhibitors with the ability to block pathological progerin-lamin A/C binding may represent a promising strategy for improving lifespan and health in both HGPS and normal aging.

100 Deals associated with JH-013

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sjogren's Syndrome	Phase 1	CN	Biotech Pharmaceutical Co., Ltd.	08 Oct 2024
Hematologic Neoplasms	Preclinical	CN	Biotech Pharmaceutical Co., Ltd.	02 Nov 2022
Systemic Lupus Erythematosus	Preclinical	CN	Biotech Pharmaceutical Co., Ltd.	02 Nov 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

JH-013

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation